Moderate radiographic hip arthritis was linked to lower odds of a meaningful gain from THA

Design

Systematic review and meta-analysis of observational studies

Population

18 studies, 9,235 patients having primary THA

Primary outcome

Patient-reported outcomes at about 12 months

Effect

Meaningful response OR 0.51 (0.36–0.72) moderate vs severe; pain SMD −0.14 (−0.51 to 0.22)

This meta-analysis pooled 18 observational studies (9,235 patients) comparing patient-reported outcomes about a year after primary total hip arthroplasty in those with moderate versus severe radiographic osteoarthritis.

Pain relief did not differ by severity (SMD −0.14, 95% CI −0.51 to 0.22). Function (SMD −0.34) and health-related quality of life (SMD −0.33) were modestly better with severe disease. In adjusted analyses, patients with moderate disease had 49% lower odds of reaching a clinically meaningful improvement (OR 0.51, 0.36–0.72). Complications did not differ. Heterogeneity was high across studies.

Patients with moderate radiographic disease still improve, but fewer cross the threshold they would notice. This does not mean refusing surgery; it means checking the pain source carefully, completing a proper course of non-operative care, and telling patients plainly that their chance of a large improvement is lower.

• Grade radiographic severity and record it in the decision for surgery
• Tell patients with moderate disease that a clinically meaningful gain is less likely
• Exclude spinal, trochanteric and other pain sources before listing
• Ensure a full trial of non-operative care in moderate disease
• Do not withhold surgery on radiographs alone when symptoms and function justify it

Why it matters

Radiographic severity is a usable predictor of who is likely to be disappointed after THA.

Don't overread it

All included studies were observational; this does not show that delaying surgery changes outcomes.

The statistics, in plain English

An odds ratio of 0.51 means patients with moderate disease had about half the odds of a clinically meaningful response. Standardised mean differences around 0.3 are small to moderate. High heterogeneity (I² 70–83%) means studies varied a lot, so the size of the gap is uncertain, though its direction was consistent.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.